See more : Zimplats Holdings Limited (ZMPLF) Income Statement Analysis – Financial Results
Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Royce Global Value Trust, Inc. (RGT) Income Statement Analysis – Financial Results
- The Real Brokerage Inc. (REAX) Income Statement Analysis – Financial Results
- Firich Enterprises Co., Ltd. (8076.TWO) Income Statement Analysis – Financial Results
- iCoreConnect Inc. (ICCT) Income Statement Analysis – Financial Results
- Bossard Holding AG (BOSN.SW) Income Statement Analysis – Financial Results
Krystal Biotech, Inc. (KRYS)
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.70M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.09M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| Gross Profit | 47.61M | -4.05M | -2.77M | -1.85M | -974.00K | 886.00K | -23.00K | -2.00K |
| Gross Profit Ratio | 93.90% | 0.00% | 0.00% | 0.00% | 0.00% | 86.27% | 0.00% | 0.00% |
| Research & Development | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| General & Administrative | 0.00 | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.40M | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Other Expenses | 12.50M | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 157.33M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Cost & Expenses | 147.93M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Interest Income | 22.62M | 5.22M | 197.00K | 832.00K | 2.99M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 5.22M | 1.49M | 0.00 | 0.00 | 1.03M | 3.15M | 7.00K |
| Depreciation & Amortization | 5.01M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| EBITDA | 17.90M | -145.20M | -65.31M | -30.32M | -18.11M | -10.75M | -4.63M | -1.14M |
| EBITDA Ratio | 35.31% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.54% | 0.00% | 0.00% |
| Operating Income | -109.73M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Operating Income Ratio | -216.43% | 0.00% | 0.00% | 0.00% | 0.00% | -1,160.27% | 0.00% | 0.00% |
| Total Other Income/Expenses | 122.62M | 5.22M | -1.30M | 832.00K | 2.99M | 1.03M | -3.15M | -7.00K |
| Income Before Tax | 12.90M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Income Before Tax Ratio | 25.44% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| Income Tax Expense | 1.97M | 34.05M | 2.73M | 1.64M | 576.14K | -20.14K | 0.00 | 0.00 |
| Net Income | 10.93M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income Ratio | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| EPS | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| EPS Diluted | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| Weighted Avg Shares Out | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
| Weighted Avg Shares Out (Dil) | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today announced that the...
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Krystal Biotech's recent approval is the only game in town, but it has a small addressable market. The biotech is developing other therapies, with most still in the early stages.
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the...
Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Call Transcript
Krystal Biotech Inc. (NASDAQ:KRYS ) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Meg Dodge - VP, Investor Relations & Corporate Communications Krish Krishnan - Chairman & Chief Executive Officer Suma Krishnan - President, Research...
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
• 284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter • Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment of CF • ...
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, will report its third...
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the...
Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement
Krystal Biotech, Inc. received FDA approval of Vyjuvek, for the treatment of patients with dystrophic epidermolysis bullosa in May of 2023. FDA IND clearance of KB408 for the treatment of patients with antitrypsin deficiency given; Phase 1 study expected to...
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high...
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the...
Source: https://incomestatements.info
Category: Stock Reports